Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

2.055 -0.055 (-2.61%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗

August 31, 2026

One of J&J's investments stands head-and-shoulders above the rest.

Via The Motley Fool

Friday's after hours session: top gainers and losers ↗

March 13, 2026

Via Chartmill

Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures

October 20, 2025

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares...

Via MarketMinute

Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts ↗

June 17, 2024

Via Benzinga

Forecasting The Future: 8 Analyst Projections For Fate Therapeutics ↗

May 06, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 30, 2025

Via Benzinga

FATE THERAPEUTICS INC (NASDAQ:FATE) Reports Mixed Q2 2025 Results with Revenue Beat and Narrower Loss ↗

August 12, 2025

Fate Therapeutics (NASDAQ:FATE) reported mixed Q2 2025 results, beating revenue estimates with $1.9M but posting a $0.29 loss per share. Progress in autoimmune and solid tumor therapies boosted...

Via Chartmill

4 Analysts Assess Fate Therapeutics: What You Need To Know ↗

May 14, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

April 14, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Via Chartmill

Where Fate Therapeutics Stands With Analysts ↗

April 11, 2024

Via Benzinga

Evaluating Fate Therapeutics: Insights From 5 Financial Analysts ↗

March 19, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics ↗

February 27, 2024

Via Benzinga

Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic ↗

April 14, 2025

CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus.

Via Stocktwits

Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗

March 05, 2025

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday ↗

November 27, 2024

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.

Via Benzinga

Topics Stocks

FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 13, 2024

FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Recap: Fate Therapeutics Q4 Earnings ↗

February 26, 2024

Via Benzinga

A Preview Of Fate Therapeutics's Earnings ↗

February 23, 2024

Via Benzinga

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? ↗

July 21, 2024

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

Via The Motley Fool

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 16, 2024

Via Benzinga

UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday ↗

July 16, 2024

Via Benzinga

This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

June 17, 2024

Via Benzinga

Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday ↗

May 16, 2024

Via Benzinga

FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 10, 2024

Via Benzinga

Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 27, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Earnings Scheduled For February 26, 2024 ↗

February 26, 2024

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.

Via Benzinga

Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock ↗

January 29, 2024

Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%.

Via InvestorPlace

Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 03, 2024

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

December 12, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.